Skip to content

Why are many US patients presenting later for HIV testing and care today than in 1990?

Good virological outcome in patients starting HIV therapy in the UK

Studies underway to find the best time to start anti-HIV therapy in those taking TB treatment

How to deliver good adherence support: lessons from round the world

ICAAC: Boosted darunavir non-inferior to boosted lopinavir after 48 weeks in treatment-naïve

European researchers develop method of calculating short-term risk of HIV disease progression

Virologically failing NNRTI regimens have higher resistance risk than failing boosted-PIs

First-line treatment choices proving challenging for African ART programmes

WHO to monitor ARV side-effects worldwide